Question explored with the scientific record
Ivermectin for squamous cell Cancer
The short version: the evidence that ivermectin treats squamous cell cancer in humans is essentially zero. What exists is a single lab study on cells and mice, plus a few case reports about parasites, not cancer.
The only direct study on ivermectin and squamous cell cancer is a 2021 lab experiment on esophageal cancer cell lines and mice [1]. It found that ivermectin killed cancer cells in a dish and slowed tumor growth in mice. That is a long way from treating a human with cancer. The dose used in mice (25 mg/kg) is far above the standard human dose for parasites (200 mcg/kg). No human trial has been done.
The other three records are about parasites, not cancer. One describes a lung cancer patient who got a worm infection after chemotherapy and was treated with ivermectin for the worms [2]. Two others describe maggot infestations in the head and neck, one in a patient with a history of nasal melanoma [3, 4]. These show ivermectin kills parasites. They say nothing about it killing cancer.
The mechanism proposed in the lab study – mitochondrial dysfunction, ROS accumulation, NF-κB inhibition – is plausible but unconfirmed in humans [1]. Many compounds kill cancer cells in a dish and fail in people. Without a human trial, the claim is untested.
My call: there is no human evidence that ivermectin treats squamous cell cancer. The lab data is a reason to study it, not a reason to use it. Confidence: high.
Sources used 4
-
Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway
Ivermectin inhibits ESCC proliferation in vitro and in vivo by inducing mitochondrial dysfunction, ROS accumulation, NF-κB inhibition, and apoptosis via the mitochondrial pathway.
DOI: 10.1186/s12885-021-09021-x -
A Case Report of Disseminated Strongyloidiasis Following Chemoradiotherapy for Lung Cancer in a Patient Living in a Non-endemic Area in Japan
This case report documents HTLV-1-associated disseminated Strongyloides stercoralis infection developing after chemoradiotherapy for lung cancer in a non-endemic area of Japan, successfully treated with daily ivermectin followed by six months of intermittent dosing, highlighting…
DOI: 10.2169/internalmedicine.5829-25 -
Head and neck myiasis: a case series and review of the literature
Nine Brazilian patients with head and neck myiasis due to Cochliomyia hominivorax are described, detailing clinical features and treatment by mechanical larval removal with debridement plus oral ivermectin, alongside a PubMed literature review that highlights socioeconomic facto…
DOI: 10.1016/j.oooo.2017.06.120 -
Ivermectin treatment for nasal myiasis complicated by orbital cellulitis: a case report
A single-patient case report describing successful management of nasal myiasis with orbital cellulitis using surgical debridement, antibiotics, and adjunctive oral/topical ivermectin, resulting in eradication of larvae and recovery of nasal and orbital structures.
DOI: 10.1186/s13256-025-05639-8